الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Nonalcoholic fatty liver disease is believed to be the most common chronic liver disease, affecting at least one-third of the population worldwide. from February 2017 to December 2019, newly diagnosed 120 patients with T2DM and proven diagnosis of NAFLD, were enrolled in a twelvemonth open-label, parallel, prospective study. Patients were divided into two groups; group 1 had HBA1c < 7.5% on diagnosis, and received vildagliptin in a dose of 50 mg twice daily and group 2 had HBA1c (7.5%-<9%) on diagnosis and received vildagliptin/metformin combination in a dose of 50 mg/1000 mg twice daily. Body mass index and fatty liver ultrasound grading were evaluated with the assay of HbA1c and serum levels of fasting and postprandial glucose, lipid profile, liver enzymes, fasting insulin, adiponectin, ferritin, creatinine, and BUN with the calculation of HOMA-IR before and after treatment. The obtained data showed that in both groups there was a significant decrease in BMI, and levels of FSG, PPSG, HBA1c, ALT, AST, TC, TG, LDL-C, fasting serum insulin, and serum ferritin. Also, HOMA-IR was significantly reduced after treatment with significant regression in fatty liver grading on the US. This study also showed a significant increase in the serum level of HDL-C and adiponectin. When we compared the efficacy of vildagliptin alone versus vildagliptin/ metformin combination, the following results were found: The vildagliptin/ metformin combination therapy caused a significant reduction in BMI, FSG, PPSG, HBA1c, ALT, AST, TC, LDL-C level, fasting insulin, HOMA-IR and ferritin than vildagliptin alone. Although there were no.